We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
AusPAR: Opdualag
Australian Public Assessment Report
Device/Product Name
Opdualag
Active ingredients
Nivolumab and Relatlimab
AusPAR Date
Published
Submission Number
PM 2021-03689-1-4
Submission Type
New combination
Decision
Approved